Global healthcare company developing medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals.
Profile & Fundamentals
Abbott Laboratories: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
Abbott Laboratories Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Company profile record
Abbott Laboratories
Common Stock · Health Care · Health Care Equipment
Company
- Company / asset
- Abbott Laboratories
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Health Care Equipment
- HQ
- 🇺🇸 United States
- Head office
- 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400
Leadership & scale
- Chief executive
- Mr. Robert B. Ford
- CEO year born
- 1974
- Full-time employees
- 122K
- Fiscal year end
- December
- IPO date
- 1978-01-13
Fundamentals snapshot
- Market Cap
- USD 171.1B
- P/E
- 31.5x
- Revenue (Q2 26)
- USD 12.6B
- Profit (Q2 26)
- USD 928.0M
- Dividend Yield
- 1.8%
- Revenue (FY 25)
- USD 44.3B
- Shares in public float
- 1.7B
- Insider ownership
- 0.49%
Reporting & identifiers
- Symbol
- ABT.NYSE
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US0028241000
- Asset ID
- equity_90606491-6d1d-54e4-989e-78da2d2dbfa6
Ownership
Shares Outstanding
Latest: 1.7B | Max: 1.8B | Min: 1.7B
Latest reported ownership snapshot
As of Oct 1, 2026Float Shares
98.67%
1.7B latest reported shares
Insider Ownership
0.49%
Latest reported insider stake
Short Float
0.01%
Latest reported short interest / float
Top Holders
Source tablesView ownership tables
Shares Outstanding
Annual reported shares outstanding; up to 10 reporting dates.
Scroll the table to see every column.
| Reporting date | Shares outstanding |
|---|---|
| 2017-01-01 | 1,746,000,000 |
| 2018-01-01 | 1,774,000,000 |
| 2019-01-01 | 1,781,000,000 |
| 2020-01-01 | 1,789,000,000 |
| 2021-01-01 | 1,782,000,000 |
| 2022-01-01 | 1,754,000,000 |
| 2023-01-01 | 1,748,000,000 |
| 2024-01-01 | 1,746,000,000 |
| 2025-01-01 | 1,747,000,000 |
| 2026-01-01 | 1,743,000,000 |
Top Holders
Available reported ownership records.
Scroll the table to see every column.
| Holder | Shares | Ownership | Reported date |
|---|---|---|---|
| BlackRock Inc | 145,687,458 | 8.42% | 2026-03-31 |
| Vanguard Capital Management, LLC | 112,949,933 | 6.53% | 2026-03-31 |
| State Street Corp | 79,575,468 | 4.6% | 2026-03-31 |
| Vanguard MStar Total Stk Mkt Idx Invest | 55,355,450 | 3.2% | 2026-08-31 |
| Vanguard Portfolio Management, LLC | 47,944,891 | 2.77% | 2026-03-31 |
| Schwab US Dividend Equity ETF™ | 47,574,842 | 2.75% | 2026-08-29 |
| Vanguard 500 Index Investor | 46,275,754 | 2.67% | 2026-08-31 |
| Charles Schwab Investment Management Inc | 45,500,055 | 2.63% | 2026-03-31 |
| Geode Capital Management, LLC | 39,148,795 | 2.26% | 2026-03-31 |
| Capital Research Global Investors | 36,908,990 | 2.13% | 2026-06-30 |
| Capital Research & Mgmt Co - Division 3 | 34,654,113 | 2% | 2026-06-30 |
| Morgan Stanley - Brokerage Accounts | 30,101,596 | 1.74% | 2026-03-31 |
| JPMorgan Chase & Co | 26,767,099 | 1.55% | 2026-03-31 |
| NORGES BANK | 23,354,911 | 1.35% | 2026-06-30 |
| iShares Core S&P 500 ETF | 23,201,902 | 1.34% | 2026-08-31 |
Earnings, Profitability & Valuation
Earnings, Profitability & Valuation
Earnings & Revenue
Earnings and Revenue Trajectory
AI Review
Abbott's recent financial headlines look deceptive at first glance. Reported accounting profit fell sharply in mid-2026, but this drop was caused by non-operating legal settlement reserves and purchase-accounting charges from acquiring Exact Sciences rather than slowing customer sales. In fact, underlying business revenue climbed to forty-six point six billion dollars over the trailing twelve months, powered by resilient high-single-digit growth across medical devices and branded generic medicines. The true operational health appears in cash generation. Abbott produced nearly eight billion dollars in trailing free cash flow, showing that its core commercial engine remains exceptionally profitable. As acquisition integration charges fade, headline earnings will re-align with cash flows, supporting steady long-term compounding.
Abbott's recent financial headlines look deceptive at first glance. Reported accounting profit fell sharply in mid-2026, but this drop was caused by non-operating legal settlement reserves and purchase-accounting charges from acquiring Exact Sciences rather than slowing customer sales. In fact, underlying business revenue climbed to forty-six point six billion dollars over the trailing twelve months, powered by resilient high-single-digit growth across medical devices and branded generic medicines. The true operational health appears in cash generation. Abbott produced nearly eight billion dollars in trailing free cash flow, showing that its core commercial engine remains exceptionally profitable. As acquisition integration charges fade, headline earnings will re-align with cash flows, supporting steady long-term compounding.
Revenue, Net Income, and Free Cash Flow
Latest: USD 44.3B | Max: USD 44.3B | Min: USD 477.0M
Valuation
P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.
Latest: 34x
Profitability & Margins
Margins and Operating Efficiency
AI Review
Abbott's profitability reveals an underlying improvement in product quality. Adjusted gross margins widened toward fifty-eight percent in mid-2026, driven by a favorable mix shift toward high-margin medical devices, glucose sensors, and precision oncology screening. These proprietary medical products carry strong pricing power, effectively counteracting raw-material inflation, hospital budget constraints, and international tariff headwinds. Although reported net income margins dipped temporarily due to acquisition financing and legal accruals, operating margins are positioned to recover toward twenty percent. As one-off merger expenses subside and automated manufacturing lowers unit sensor costs, operational leverage will drive accelerated profit growth across the five-year investment horizon.
Abbott's profitability reveals an underlying improvement in product quality. Adjusted gross margins widened toward fifty-eight percent in mid-2026, driven by a favorable mix shift toward high-margin medical devices, glucose sensors, and precision oncology screening. These proprietary medical products carry strong pricing power, effectively counteracting raw-material inflation, hospital budget constraints, and international tariff headwinds. Although reported net income margins dipped temporarily due to acquisition financing and legal accruals, operating margins are positioned to recover toward twenty percent. As one-off merger expenses subside and automated manufacturing lowers unit sensor costs, operational leverage will drive accelerated profit growth across the five-year investment horizon.
Profitability Margins
Latest: 55.5% | Max: 55.5% | Min: 1.7%
Latest Profitability Ratios as of 2025-12-31
Gross Margin
55.5%
Gross profit / revenue
Operating Margin
18.2%
Operating income / revenue
Net Margin
14.7%
Net income / revenue
FCF Margin
16.7%
Free cash flow / revenue
Source tablesView earnings, profitability & valuation tables
Revenue, Net Income, and Free Cash Flow
Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.
Scroll the table to see every column.
| Period end | Revenue (USD) | Net income (USD) | Free cash flow (USD) |
|---|---|---|---|
| 2016-12-31 | 20,853,000,000 | 1,400,000,000 | 2,082,000,000 |
| 2017-12-31 | 27,390,000,000 | 477,000,000 | 4,435,000,000 |
| 2018-12-31 | 30,578,000,000 | 2,368,000,000 | 4,906,000,000 |
| 2019-12-31 | 31,904,000,000 | 3,687,000,000 | 4,498,000,000 |
| 2020-12-31 | 34,608,000,000 | 4,495,000,000 | 5,724,000,000 |
| 2021-12-31 | 43,075,000,000 | 7,071,000,000 | 8,648,000,000 |
| 2022-12-31 | 43,653,000,000 | 6,933,000,000 | 7,804,000,000 |
| 2023-12-31 | 40,109,000,000 | 5,723,000,000 | 5,059,000,000 |
| 2024-12-31 | 41,950,000,000 | 13,402,000,000 | 6,351,000,000 |
| 2025-12-31 | 44,328,000,000 | 6,524,000,000 | 7,395,000,000 |
Published P/E Ratio
Published valuation snapshots retain each observation's earnings basis.
Scroll the table to see every column.
| Period end | P/E (times earnings) | Earnings basis |
|---|---|---|
| 2025-12-31 | 33.55 | Trailing four quarters |
| 2024-12-31 | 14.74 | Trailing four quarters |
| 2023-12-31 | 33.62 | Trailing four quarters |
| 2022-12-31 | 27.78 | Annual net income |
| 2021-12-31 | 35.47 | Annual net income |
Profitability Margins
Matching annual reporting dates. Values are percentages.
Scroll the table to see every column.
| Period end | Gross margin (%) | Operating margin (%) | Net margin (%) | Free cash flow margin (%) |
|---|---|---|---|---|
| 2016-12-31 | 53.92 | 15.58 | 6.71 | 9.98 |
| 2017-12-31 | 47.7 | 7.2 | 1.74 | 16.19 |
| 2018-12-31 | 51.75 | 12.57 | 7.74 | 16.04 |
| 2019-12-31 | 52.32 | 14.39 | 11.56 | 14.1 |
| 2020-12-31 | 50.21 | 15.29 | 12.99 | 16.54 |
| 2021-12-31 | 53.89 | 21.36 | 16.42 | 20.08 |
| 2022-12-31 | 51.14 | 19.16 | 15.88 | 17.88 |
| 2023-12-31 | 49.96 | 16.04 | 14.27 | 12.61 |
| 2024-12-31 | 50.83 | 16.27 | 31.95 | 15.14 |
| 2025-12-31 | 55.51 | 18.16 | 14.72 | 16.68 |
Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Source: eodhd. Snapshot retrieved 2026-10-01.
Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.